309 related articles for article (PubMed ID: 16513827)
1. Recombinant human insulin-like growth factor-I treatment inhibits gluconeogenesis in a transgenic mouse model of type 2 diabetes mellitus.
Pennisi P; Gavrilova O; Setser-Portas J; Jou W; Santopietro S; Clemmons D; Yakar S; LeRoith D
Endocrinology; 2006 Jun; 147(6):2619-30. PubMed ID: 16513827
[TBL] [Abstract][Full Text] [Related]
2. Recombinant human insulin-like growth factor I treatment for 1 week improves metabolic control in type 2 diabetes by ameliorating hepatic and muscle insulin resistance.
Cusi K; DeFronzo R
J Clin Endocrinol Metab; 2000 Sep; 85(9):3077-84. PubMed ID: 10999789
[TBL] [Abstract][Full Text] [Related]
3. Phloridzin improves hyperglycemia but not hepatic insulin resistance in a transgenic mouse model of type 2 diabetes.
Zhao H; Yakar S; Gavrilova O; Sun H; Zhang Y; Kim H; Setser J; Jou W; LeRoith D
Diabetes; 2004 Nov; 53(11):2901-9. PubMed ID: 15504971
[TBL] [Abstract][Full Text] [Related]
4. Effects of insulin-like growth factor I (IGF-I) therapy on body composition and insulin resistance in IGF-I gene deletion.
Woods KA; Camacho-Hübner C; Bergman RN; Barter D; Clark AJ; Savage MO
J Clin Endocrinol Metab; 2000 Apr; 85(4):1407-11. PubMed ID: 10770174
[TBL] [Abstract][Full Text] [Related]
5. Peroxisome proliferator-activated receptor-alpha agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis.
Kim H; Haluzik M; Asghar Z; Yau D; Joseph JW; Fernandez AM; Reitman ML; Yakar S; Stannard B; Heron-Milhavet L; Wheeler MB; LeRoith D
Diabetes; 2003 Jul; 52(7):1770-8. PubMed ID: 12829645
[TBL] [Abstract][Full Text] [Related]
6. Effects of combined recombinant insulin-like growth factor (IGF)-I and IGF binding protein-3 in type 2 diabetic patients on glycemic control and distribution of IGF-I and IGF-II among serum binding protein complexes.
Clemmons DR; Sleevi M; Allan G; Sommer A
J Clin Endocrinol Metab; 2007 Jul; 92(7):2652-8. PubMed ID: 17426090
[TBL] [Abstract][Full Text] [Related]
7. Insulin-like growth factor-I improves glucose and lipid metabolism in type 2 diabetes mellitus.
Zenobi PD; Jaeggi-Groisman SE; Riesen WF; Røder ME; Froesch ER
J Clin Invest; 1992 Dec; 90(6):2234-41. PubMed ID: 1469083
[TBL] [Abstract][Full Text] [Related]
8. Short-term effects of recombinant human insulin-like growth factor I on metabolic control of patients with type II diabetes mellitus.
Schalch DS; Turman NJ; Marcsisin VS; Heffernan M; Guler HP
J Clin Endocrinol Metab; 1993 Dec; 77(6):1563-8. PubMed ID: 8263142
[TBL] [Abstract][Full Text] [Related]
9. Recombinant human insulin-like growth factor I has significant anabolic effects in adults with growth hormone receptor deficiency: studies on protein, glucose, and lipid metabolism.
Mauras N; Martinez V; Rini A; Guevara-Aguirre J
J Clin Endocrinol Metab; 2000 Sep; 85(9):3036-42. PubMed ID: 10999782
[TBL] [Abstract][Full Text] [Related]
10. Effect of magnesium sulfate administration to improve insulin resistance in type 2 diabetes animal model: using the hyperinsulinemic-euglycemic clamp technique.
Sohrabipour S; Sharifi MR; Sharifi M; Talebi A; Soltani N
Fundam Clin Pharmacol; 2018 Dec; 32(6):603-616. PubMed ID: 29869808
[TBL] [Abstract][Full Text] [Related]
11. Low-dose growth hormone treatment combined with diet restriction decreases insulin resistance by reducing visceral fat and increasing muscle mass in obese type 2 diabetic patients.
Nam SY; Kim KR; Cha BS; Song YD; Lim SK; Lee HC; Huh KB
Int J Obes Relat Metab Disord; 2001 Aug; 25(8):1101-7. PubMed ID: 11477493
[TBL] [Abstract][Full Text] [Related]
12. Dose-dependent effects of recombinant human insulin-like growth factor (IGF)-I/IGF binding protein-3 complex on overnight growth hormone secretion and insulin sensitivity in type 1 diabetes.
Saukkonen T; Amin R; Williams RM; Fox C; Yuen KC; White MA; Umpleby AM; Acerini CL; Dunger DB
J Clin Endocrinol Metab; 2004 Sep; 89(9):4634-41. PubMed ID: 15356074
[TBL] [Abstract][Full Text] [Related]
13. The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation.
Lo JC; Mulligan K; Noor MA; Schwarz JM; Halvorsen RA; Grunfeld C; Schambelan M
J Clin Endocrinol Metab; 2001 Aug; 86(8):3480-7. PubMed ID: 11502767
[TBL] [Abstract][Full Text] [Related]
14. Muscle-specific overexpression of CD36 reverses the insulin resistance and diabetes of MKR mice.
Héron-Milhavet L; Haluzik M; Yakar S; Gavrilova O; Pack S; Jou WC; Ibrahimi A; Kim H; Hunt D; Yau D; Asghar Z; Joseph J; Wheeler MB; Abumrad NA; LeRoith D
Endocrinology; 2004 Oct; 145(10):4667-76. PubMed ID: 15231693
[TBL] [Abstract][Full Text] [Related]
15. MKR mice are resistant to the metabolic actions of both insulin and adiponectin: discordance between insulin resistance and adiponectin responsiveness.
Kim CH; Pennisi P; Zhao H; Yakar S; Kaufman JB; Iganaki K; Shiloach J; Scherer PE; Quon MJ; LeRoith D
Am J Physiol Endocrinol Metab; 2006 Aug; 291(2):E298-305. PubMed ID: 16507604
[TBL] [Abstract][Full Text] [Related]
16. Effects of recombinant human IGF-I/IGF-binding protein-3 complex on glucose and glycerol metabolism in type 1 diabetes.
Saukkonen T; Shojaee-Moradie F; Williams RM; Amin R; Yuen KC; Watts A; Acerini CL; Umpleby AM; Dunger DB
Diabetes; 2006 Aug; 55(8):2365-70. PubMed ID: 16873702
[TBL] [Abstract][Full Text] [Related]
17. Effects of low-dose recombinant human insulin-like growth factor-I on insulin sensitivity, growth hormone and glucagon levels in young adults with insulin-dependent diabetes mellitus.
Acerini CL; Harris DA; Matyka KA; Watts AP; Umpleby AM; Russell-Jones DL; Dunger DB
Metabolism; 1998 Dec; 47(12):1481-9. PubMed ID: 9867078
[TBL] [Abstract][Full Text] [Related]
18. Long-term effect of recombinant human insulin-like growth factor I on metabolic and growth control in a patient with leprechaunism.
Nakae J; Kato M; Murashita M; Shinohara N; Tajima T; Fujieda K
J Clin Endocrinol Metab; 1998 Feb; 83(2):542-9. PubMed ID: 9467572
[TBL] [Abstract][Full Text] [Related]
19. GABA dramatically improves glucose tolerance in streptozotocin-induced diabetic rats fed with high-fat diet.
Sohrabipour S; Sharifi MR; Talebi A; Sharifi M; Soltani N
Eur J Pharmacol; 2018 May; 826():75-84. PubMed ID: 29391158
[TBL] [Abstract][Full Text] [Related]
20. Oleanolic acid improves hepatic insulin resistance via antioxidant, hypolipidemic and anti-inflammatory effects.
Wang X; Liu R; Zhang W; Zhang X; Liao N; Wang Z; Li W; Qin X; Hai C
Mol Cell Endocrinol; 2013 Aug; 376(1-2):70-80. PubMed ID: 23791844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
